Back to top
more

iRadimed (IRMD)

(Delayed Data from NSDQ)

$43.67 USD

43.67
44,129

-0.27 (-0.61%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $43.64 -0.03 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

by Zacks Equity Research

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

IRadimed (IRMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 11.11% and 4.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Buys Richmond Post-Acute Care Facility

by Zacks Equity Research

Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.

Zacks.com featured highlights include MercadoLibre, iRadimed, Northeast Community Bancorp and AAON

by Zacks Equity Research

MercadoLibre, iRadimed, Northeast Community Bancorp and AAON are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

4 Best Profitable Stocks to Buy Banking on Net Income Ratio

by Tirthankar Chakraborty

MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ratio.

IRadimed (IRMD) Q4 Earnings Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 3.23% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic, Inc. (HOLX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 Reasons Growth Investors Will Love iRadimed (IRMD)

by Zacks Equity Research

iRadimed (IRMD) possesses solid growth attributes, which could help it handily outperform the market.

Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023

by Zacks Equity Research

Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in a bid to drive pharmacy revenues.

Here is Why Growth Investors Should Buy iRadimed (IRMD) Now

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The Zacks Analyst Blog Highlights ShockWave Medical, iRadimed and Tactile Systems Technology

by Zacks Equity Research

ShockWave Medical, iRadimed and Tactile Systems Technology are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

3 Medical Instruments Stocks With Potential to Outperform

by Indrajit Bandyopadhyay

Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.

IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 56.10% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 27.4% in 4 Weeks, Here's Why the Trend Might Reverse for iRadimed (IRMD)

by Zacks Equity Research

iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

IRadimed (IRMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 4.76% and 0.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Indivior PLC (INVVY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Indivior PLC (INVVY) and iRadimed (IRMD) have performed compared to their sector so far this year.

Here's Why Momentum in iRadimed (IRMD) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how iRadimed (IRMD) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Here's Why Momentum in iRadimed (IRMD) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

iRadimed (IRMD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.